The Patient Advisory Committee of INNODIA represents the voice to the experiences, opinions and desires of the patients to help ensure that INNODIA’s goals and strategy are closely aligned with the goals of people living with, and affected by type 1 diabetes.

JANUARY 2018

NEW BIOMARKER FOR TYPE 1 DIABETES

A NEW AND PROMISING BIOMARKERS FOR BETA CELL IMAGING IN TYPE 1 DIABETES HAS BEEN DISCOVERED

It is an important discovery in the context of stratification of patients according to remaining beta cell mass and consequently the level of insulin possibly secreted. It will help in evaluation of pharmaceutical agents that modulate beta cell mass. More specifically it will be extremely helpful before and after evaluation of beta cell mass of patients and participants in clinical trials to preserve/restore beta cell mass.

These beta cell imaging markers should be unaffected by degranulation, which is the case for insulin or C-peptide and will be useful for long term follow up of transplanted human islets.

The team is presently undergoing pre-clinical testing and looking at imaging of human islets implanted in immunodeficient mice.

INNODIA proposes an innovative approach to realize a decisive step towards type 1 diabetes prevention and cure. INNODIA develops European infrastructures, establish a tight collaborative network of basic and clinical researchers, advances the development and application of novel methodologies, establishes a unique integrated database and conceives innovative clinical trial designs.

INNODIA is putting together a consortium of the leading clinical and basic science researchers on type 1 diabetes in Europe.

DO YOU WANT TO PARTICIPATE?

Have you been diagnosed with type 1 diabetes in the last 6 weeks?

OR Do you have a parent, child, sibling with type 1 diabetes?

See the nearest clinical center on www.innodia.eu